Certolizumab pegol reduces signs and symptoms of axial spondyloarthritis: Study
Certolizumab pegol, a PEGylated anti-TNF (Tumour Necrosis Factor alpha), is indicated to treat moderate to severe active rheumatoid arthritis (RA), in combination with methotrexate, in adult patients when
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.